[go: up one dir, main page]

WO1991005057A1 - Production de cd4 dans pichia pastoris - Google Patents

Production de cd4 dans pichia pastoris Download PDF

Info

Publication number
WO1991005057A1
WO1991005057A1 PCT/US1990/005520 US9005520W WO9105057A1 WO 1991005057 A1 WO1991005057 A1 WO 1991005057A1 US 9005520 W US9005520 W US 9005520W WO 9105057 A1 WO9105057 A1 WO 9105057A1
Authority
WO
WIPO (PCT)
Prior art keywords
pastoris
gene
dna
glycoprotein
encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1990/005520
Other languages
English (en)
Inventor
Richard Gordon Buckholz
Russell Arthur Brierley
Mary Susan Odiorne
Robert Steven Siegel
Lillian Margaret Wondrack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIBIA Neurosciences Inc
Original Assignee
Salk Institute Biotechnology Industrial Associates Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute Biotechnology Industrial Associates Inc filed Critical Salk Institute Biotechnology Industrial Associates Inc
Publication of WO1991005057A1 publication Critical patent/WO1991005057A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Definitions

  • This invention relates to the field of recombinant DNA technology. More particularly, the invention concerns the development of Pichia pastoris yeast strains capable of high-level production and secretion of at least a portion of the human T-cell receptor molecule CD4 (also referred to as T4 protein) containing the site of interaction between CD4 and the human immunodeficiency virus HIV.
  • CD4 also referred to as T4 protein
  • the CD4 protein is a glycoprotein of approximately 60,000 daltons molecular weight that is expressed on the cell membrane of the mature, thy us-
  • the CD4 molecule consists of four tandem extracellular domains which contain significant sequence and structural homology with the variable (V) and joining (J) regions of
  • the molecule was originally described as a marker distinguishing the helper/inducer subset of mature
  • MHC major histocompatibility complex
  • T4 gene-in human lymphoid and epithelial cells and the ability of previously T4" cells to bind to and become infected with HIV, after they had been transformed with recombinant vectors and thereby became T4 + cells.
  • the 5 authors also showed that recombinant human CD4 on mouse cells did not allow for HIV infection, although it bound HIV.
  • Further publications concerning the recombinant production of soluble CD4 protein, and the ability of the recombinant product to interact with HIV and thus inhibit infection are: Smith et al.. Science 238, 1704 (1987) ; Fisher et al.. Nature 331. 76 (1988) ; Hussey et al.. Nature 331. 78 (1988) ; Deen et al..
  • CD4 The specific sequences of CD4 and the HIV virus that are required for interaction have also been identified.
  • the component of HIV that mediates binding of the virus to CD4 is the surface glycoprotein, gpl20 [Lasky et al.. Cell 50. 975 (1987)].
  • gpl20 The component of HIV that mediates binding of the virus to CD4 is the surface glycoprotein, gpl20 [Lasky et al.. Cell 50. 975 (1987)].
  • antibodies raised against gpl20 have been ineffective in blocking viral infection either in vitro or in vivo. The inability to block is probably related to the heterogeneity seen among gpl20 protein sequences from different viral isolates.
  • Antibodies raised against gpl20 from one HIV isolate will not necessarily recognize gpl20 from a different isolate.
  • the CD4-binding region of gpl20 is not accessible to antibody molecules and thus may be capable of binding CD4 even if antibody does bind gpl20.
  • V 1f comprising the N-terminal 106 amino acids of mature CD4, as the site of interaction with gpl20 [Berger et al. , PNAS 85. 2357 (1988)]. Further analyses of binding, using mutant CD4 proteins, truncated derivatives of CD4, HIV, and purified gpl20 have narrowed this assignment to amino acid residues 40-48 within V, [Peterson and Seed, Cell 54, 65 (1988)]. However, other conserved structures within V, are probably essential to achieve the highest affinity binding of HIV to CD4. The affinity of the HIV virus for CD4 makes this molecule a rational target for development of an effective AIDS therapy or prevention.
  • CD4-expressing T- cells It might be possible to block the entry of HIV into CD4-expressing T- cells through the use of anti-CD4 antibodies or the presence of excess soluble CD4 molecules.
  • the CD4 receptor present on the T-cell surface may be unable to bind the HIV gpl20 "ligand" if the CD4 is first bound by antibody.
  • an excess of soluble CD4 molecules is present in a sample comprised of CD4-expressing T-cells and HIV, then a large proportion of virus might bind to the soluble CD4, be inhibited from binding the cell-associated receptor, and viral infection might be lessened or prohibited.
  • Pichia pastoris yeast expression system developed in part by scientists at SIBIA, the assignee of the present patent application, has proved to be instrumental in the production of several heterologous proteins. This system is based on methanol-regulated promoters and high cell density fermentation. Because Pichia pastoris is a methylotrophic yeast, it has metabolic pathways that respond to and regulate methanol utilization. A key enzyme in the methanol utilization pathway is alcohol oxidase, a protein encoded by two genes, AOX1 and AOX2. When Pichia cells are grown in the presence of methanol, the AOX1 and AOX2 genes are transcribed and a large amount of alcohol oxidase protein is produced. The high level of AOX gene expression is 5.
  • methanol-responsive AOX1 gene promoter which is activated in the presence of methanol.
  • This promoter is highly expressed and tightly regulated (see e.g. the European Patent Application No. 85113737.2, published June 4, 1986, under No. 183 071).
  • heterologous proteins e.g., hepatitis B surface antigen [Cregg et al. , Supra], bovine lysozyme [Digan et al. , Developments in Industrial Microbiolo ⁇ y 29, 59 (1988) ; Digan et al. , Bio Techno1ocry 1_. 160 (1989) , and Saccharomyces cerevisiae invertase
  • the present invention relates to the production of a secreted soluble form of CD4 protein, containing the site of interaction between CD4 and the human immunodeficiency virus (HIV) in Pichia pastoris (P. pastoris) .
  • HAV human immunodeficiency virus
  • the present invention relates to a _i. pastoris yeast cell containing in its genome at least one copy of a DNA sequence operably encoding in P. pastoris at least a portion of human CD4 glycoprotein, containing the site of interaction between CD4 and HIV, in operational association with a DNA sequence encoding a signal sequence which functions to direct secretion of the encoded glycoprotein in I ⁇ _ pastoris , both under the regulation of a promoter region of a P_j_ pastoris gene.
  • the signal sequence of the S_i. cerevisiae alpha-mating factor (AMF) gene is a preferred signal sequence.
  • the present invention concerns a DNA fragment which may be contained within, or may itself be, a circular plasmid, and which comprises at least one copy of an expression cassette comprising in the direction of transcription, a promoter region of a first P_ s _ pastoris gene, a DNA sequence encoding in P. pastoris at least a portion of human CD4 glycoprotein containing the site of interaction between CD4 and the HIV virus, preceeded by a DNA sequence encoding a signal sequence directing the secretion of said glycoprotein or a portion thereof in JP ⁇ . pastoris. and a transcription terminator of a second ⁇ ⁇ _ pastoris gene, said first and second P ⁇ . pastoris genes being identical or different, and the segments of said expression cassette being in operational association.
  • the DNA sequence preceeding the CD4 glycoprotein gene preferably is a DNA sequence encoding the S__. cerevisiae AMF pre-pro sequence followed by a DNA sequence encoding AMF processing site lys-arg. Expression vectors containing such DNA sequences are also within the scope of the invention.
  • the invention relates to a process for producing and secreting at least a portion of human CD4 glycoprotein, containing the site of interaction between CD4 and the virus HIV, into the culture medium.
  • P_j_ pastoris transformants containing in their genome at least one copy of a DNA sequence operably encoding in Pj_ pastoris at least a portion of human CD4 glycoprotein, containing the site of interaction between CD4 and the virus HIV, in operational association with a DNA sequence encoding a signal sequence which functions to direct secretion of the encoded CD4 or CD4 portion in I___ pastoris (the S. cerevisiae AMF pre-pro sequence being preferred) , both under the regulation of a promoter region of a
  • P. pastoris gene are grown under conditions allowing the expression of the DNA sequences in £ ⁇ pastoris and secretion of the CD4 glycoprotein into the culture medium in a substantially pure form devoid of degradation products.
  • Figure 1 shows the nucleotide sequence and amino acid sequence of the S_ s _ cerevisiae alpha-mating factor (AMF) pre-pro gene segment.
  • AMF alpha-mating factor
  • Figure 2 shows the nucleotide sequence and the deduced amino acid sequence of a 482 bp DNA fragment encoding amino acids 1 - 106 of mature CD4 along with its leader sequence.
  • Figure 3 illustrates the construction of the Pichia pastoris expression vector, pSCD103 for the production of human CD4-V 1 .
  • Figure 4 shows the nucleotide and amino acid 5. sequence of the EcoRI insert of pSCD103.
  • Figure 5 is a restriction map of plasmid pA0815
  • Figure 6 shows the cell wet weight over time for fermentation Runs 568, 570, and 571.
  • Figure 7 shows the time course of fermentation 0 Run 593 of the two-copy Mut+ strain, G+SCD103S16.
  • FIG. 7A is plotted against time. The expression level was determined by the quantitative Western blot assay.
  • Figure 8 is a silver-stained gel, using reducing conditions of V 1 standard and Pichia pastoris fermentor broth. Lanes 1-4 (numbered consecutively from left to right) contain 100, 200, 300 or 400 ng V 1 standard, respectively. Lane 6 is 7.5 ⁇ l of G+SCD103S16 fermentor broth; lanes 7 and 8 are 5 ⁇ l of G-PA0815 fermentor broth containing 100 ng or 200 ng V, standard, respectively.
  • Lane 10 is 3.75 ⁇ l of G+SCD103S16 broth with 3.75 ⁇ l of G-PA0815 broth; lanes 11 and 12 are 3.75 ⁇ l and 7.5 ⁇ l of G-PA0815 broth, alone.
  • Lane 13 is pre- stained molecular size standards obtained from Diversified Biotech, Newton Centre, MA. They are Low Range Standards #SDS-100P and are: trypsin inhibitor, 20,400; myoglobin, 16,949; CNBr cleavage fragments of myoglobin, Fragment IV, 14,404; Fragment III, 8,159; Fragment II, 6,214; Fragment I 2,152. These standards are included to denote relative positions of sample bands on the gel and have not been used to estimate molecular mass. Lanes 5 and 9 contain broth from a fermentation run of strain G+SCD103S16 using slightly different conditions than those reported in the Examples.
  • Figure 9 shows the results of N-terminal sequence analysis of rCD4-V, produced in Pichia pastoris 5 . compared with the published N-terminal sequence for mature human CD4.
  • Pichia rCD4-V 1 was isolated from a gel similar to the one in Figure 8, and sequenced as described in Example 4b.
  • Figure 10 shows the result of stability test 0 performed on rCD4-V_, produced in Pichia pastoris.
  • One hundred microliter samples of G+SCD103S16 broth were treated under the following conditions, before 10 ⁇ l was separated on SDS-PAGE and subjected to immunoblotting with polyclonal sCD4 antibody. All broth samples were 5 frozen immediately upon removal from the fermentor. The sample in lane 1 was thawed just prior to SDS-PAGE. Lanes 2-4 contain samples at pH 2.5, lanes 5-7 contain samples that had been adjusted to pH 5.0 upon thawing.
  • Figure 11 shows the nucleotide sequence of the 5 human CD4 cDNA and the translated sequence of the CD4 protein.
  • first variable region V
  • V., 0 region and synonymous expressions, alone or in combination with other terms, are used throughout the specification and claims to refer to a DNA sequence including at least the first 106 N-terminal amino acids of mature human CD4 (as shown in Figure 11) .
  • polypeptides deficient in one or more amino acids in the amino acid sequence reported in the literature, or polypeptides containing additional amino acids, or polypeptides in which one or more amino acids in the amino acid sequence of the V_, region of CD4 are replaced by other amino acids are within the scope of the definition used herein, provided that they exhibit the functional activity of V 1# in particular preserve its HIV- binding properties.
  • amino acid sequence of CD4 or its respective regions are replaced by other amino acids are within the scope of the definition used herein, provided that they exhibit the functional activity of CD4, in particular preserve its HIV-binding properties.
  • the definition used in 0 connection with the present invention is intended to embrace all the allelic variations of CD4.
  • derivatives obtained by simple modification of the amino acid sequence of the naturally occurring protein, e.g. by way of site-directed mutagenesis or 5 other standard procedures are included.
  • amino acid sequence operably encoding in Pichia pastoris at least a portion of human CD4 glycoprotein, containing the site of interaction between CD4 and the human immunodeficiency virus HIV refers to DNA sequences encoding in Pichia pastoris "at least a portion of human CD4 glycoprotein, containing the site of interaction between CD4 and the human immunodeficiency virus HIV” such as the "first variable (V ⁇ region", as 5 hereinabove defined.
  • This sequence contains but is not restricted to, the DNA sequence encoding residues 16 through 84 of the mature CD4 protein, which are contained within the first disulfide-bonded, covalently closed peptide loop of CD4.
  • Such sequences may be obtained by 0 chemical synthesis or by transcription of a messenger RNA (mRNA) corresponding to CD4 or a portion thereof to a complementary DNA (cDNA) and converting the latter into a double stranded cDNA.
  • mRNA messenger RNA
  • cDNA complementary DNA
  • the CD4 sequences may be obtained through the use of polymerase chain 5 reaction (PCR) on genomic DNA encoding at least the V, region.
  • PCR polymerase chain 5 reaction
  • the mRNA can be isolated for example, from T4 + transformed fibroplasts as described by Maddon et al.. Supra (1985) .
  • Chemical synthesis of a gene for human CD4 or a portion thereof is, for example, disclosed by Jameson et al. , Science 240, 1335 (1988) ; Litsen et al..
  • the requisite DNA sequence can 5. also be removed, for example, by restriction enzyme digest of known vectors harboring the desired gene. Examples of such vectors and the means for their preparation can be taken from the following publications: Smith et al.. Supra; Fisher et al. , Supra; Hussey et al..
  • Example 1 of the present application a 482 bp DNA fragment encoding the V 1 portion of human CD4 was excised from a 2.2 kb linear Bglll-Nhel DNA fragment by digestion with EcoRI and Xbal.
  • the CD4-V the CD4-V
  • 15 encoding DNA fragment can be removed from other known DNA fragments as well.
  • a 682 bp EcoRI-Nhel fragment from pT4B is disclosed in Maddon et al. , Cell 42. 93 (1985) .
  • the V.,-encoding sequence can be readily obtained from this fragment by digestion with EcoRI and
  • amino acids which occur in the various amino acid sequences referred to in the specification have their usual, three- and one-letter abbreviations, routinely used in the art, i.e.:
  • the promoter region employed to drive the expression of a gene encoding at least a portion of CD4, preferably CD4-V, is derived from a methanol-regulated alcohol oxidase gene of ⁇ . pastoris.
  • P. pastoris is known to contain two functional alcohol oxidase genes:
  • AOXl alcohol oxidase I
  • A0X2 alcohol oxidase II
  • the AOXl gene including its promoter, has been isolated and thoroughly characterized [Ellis et al.. Mol. Cell. Biol. 5 , 1111
  • the expression cassette used for transforming P. pastoris cells contains, in addition to the P. pastoris promoter and the CD4 (CD4-V,) encoding DNA sequence, a DNA sequence encoding a signal sequence
  • directing the secretion of the CD4 glycoprotein or a portion thereof in £ ⁇ _ pastoris preferably a DNA encoding the in-reading frame S___ cerevisiae AMF pre-pro sequence, and a DNA sequence encoding AMF processing site, lys-arg (also referred to as lys-arg encoding sequence) and a
  • S. cerevisiae AMF pre-pro sequence is preferred, other signal sequences suitable for directing foreign protein secretion in ⁇ _ pastoris may also be used.
  • Such sequences are, for example, the Saccharomyces cerevisiae invertase signal sequence.
  • the Sj. cerevisiae alpha-mating factor is a 13- residue peptide, secreted by cells of the "alpha” mating type, that acts on cells of the opposite "a” mating type to promote efficient conjugation between the two cell types and thereby formation of "a-alpha” diploid cells [Thorner et al.. The Molecular Biology the Yeast Saccharomyces. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 143 (1981)].
  • the AMF pre-pro sequence is a leader sequence contained in the AMF precursor molecule, which, together with the lys-arg encoding sequence is necessary for proteolytic processing and secretion (see e.g. Brake et al.. Supra) .
  • the AMF pre-pro sequence, including the lys-arg encoding sequence is a 255 bp fragment which is illustrated in Figure 1.
  • the P ⁇ . pastoris transcription terminator used in accordance with the present invention has a subsegment which encodes a polyadenylation signal and polyadenylation site in the transcript and/or a subsegment which provides a transcription termination signal for transcription from the promoter used in the expression cassette according to the invention (the term "expression cassette” as used herein and throughout the specification and claims refers to a DNA sequence which includes sequences functional for expression and the secretion processes) .
  • the entire transcription terminator is taken from a Pj_ pastoris protein-encoding gene, which may be the same or different from the
  • P. pastoris gene which is the source of the £__. pastoris promoter used according to the invention.
  • the DNA fragments according to the invention further comprise a selectable marker gene.
  • a selectable marker gene functional in
  • P. pastoris may be employed, i.e., any gene which confers a phenotype upon I ⁇ . pastoris cells thereby allowing them to be identified and selectively grown from among a vast majority of untransformed cells.
  • Suitable selectable marker genes include, for example, selectable marker systems composed of an auxotrophic mutant ⁇ _ pastoris 5 . host strain and a wild type biosynthetic gene which complements the host's defect.
  • selectable marker systems composed of an auxotrophic mutant ⁇ _ pastoris 5 . host strain and a wild type biosynthetic gene which complements the host's defect.
  • For transformation of his4 " _ s _ pastoris strains for example, the S_ ⁇ cerevisiae or Pjj. pastoris HIS4 gene, or for transformation of arg4 " mutants the S__. cerevisiae ARG4 gene or the p__. pastoris 0 ARG4 gene, may be employed.
  • expression vector includes vectors capable of expressing DNA sequences contained therein, where such sequences are in operational association with other sequences capable of effecting their expression, 5 i.e. promoter sequences.
  • expression vectors usually used in recombinant DNA technology are often in the form of "plasmids", i.e. circular, double-stranded DNA loops which, in their vector form, are not bound to the chromosome.
  • vectors i.e. circular, double-stranded DNA loops which, in their vector form, are not bound to the chromosome.
  • the segments of the expression cassette are "in operational association".
  • the DNA sequence encoding CD4 or any portion thereof as hereinabove defined is positioned and oriented functionally with respect to the promoter, the DNA encoding a signal sequence, preferably 0 the S_ ⁇ . cerevisiae AMF pre-pro sequence, and the DNA sequence encoding AMF processing-site, lys-arg and the transcription terminator, so that the polypeptide encoding segment is transcribed, under regulation of the promoter region, into a transcript capable of providing, 5 upon translation the desired polypeptide in P_j_ pastoris. Because of the presence of the signal sequence, e.g.
  • the AMF pre-pro sequence, the expressed product, CD4 or a portion thereof, as hereinabove defined, is found as a secreted entity in the culture medium, properly processed away from the AMF pre-pro sequence.
  • Appropriate reading frame positioning and orientation of the various segments 5. of the expression cassette are within the knowledge of persons of ordinary skill in the art; further details are given in the Examples.
  • the DNA fragment provided by the present invention may include sequences allowing for its 0 replication and selection in bacteria, especially E. coli. In this way, large quantities of the DNA fragment can be produced by replication in bacteria.
  • culture means a propagation of cells in a medium conductive to their growth, and all sub- cultures thereof.
  • subculture refers to a culture of cells grown from cells of another culture (source culture) , or any subculture of the source culture, regardless of the number of subculturings which have been performed between the subculture of interest and the source culture.
  • the expression cassettes are generally transformed into the ⁇ _ pastoris cells by the whole-cell lithium chloride yeast transformation system [Ito et al.. Agric. Biol. Chem. 48. 0 341 (1984)], with minor modification necessary for adaptation to P. pastoris.
  • the spheroplast technique described by Cregg et al.,
  • Mol. Cell. Biol. 5 , 3376 (1985) can also be used for the transformation of P ⁇ _ pastoris cells.
  • the whole-cell 5 lithium chloride method is more convenient in that it does not require the generation and maintenance of ⁇ pheroplasts.
  • RNA for Northern blot analysis was prepared essentially as described by Zitomer et al.. J. Biol. Chem. 251. 6320 (1976) .
  • the V., region of the human CD4 molecule is produced in Pichia pastoris.
  • This V 1 region contains a single disulfide bond between two cysteine residues, which are located near the N- and C-termini, respectively.
  • the heterologous protein expression system used for CD4-V 1 production preferably utilizes the promoter derived from the methanol-regulated AOXl gene of
  • the expression cassette preferably comprises, in operational association, a
  • the host cells to be transformed with a linear vector comprising the expression cassette are ⁇ . pastoris cells having at least one mutation that can be complemented with a marker gene present on a transforming DNA fragment.
  • his4 " (GS115) auxotrophic mutant P. pastoris strains are employed.
  • the expression cassette is inserted into a 5 . plasmid containing a marker gene complementing the host's defect.
  • pBR322-based plasmids e.g. pA0815 are preferred.
  • Plasmid pA0815 comprising the CD4-V., expression/secretion cassette is called pSCD103. The construction of this plasmid is disclosed in
  • the expression cassette is preferably integrated into the host genome by means of the homologous sequences present on the transforming DNA.
  • the AOXl gene is replaced with the expression cassette, thus decreasing the transformant's ability to utilize methanol.
  • a slow growth rate on methanol is maintained by expression of the AOX2 gene product.
  • the 25 integrated into the AOXl locus by site-directed recombination can be identified by first screening for the presence of the complementing gene. This is preferably accomplished by growing the cells in a media lacking the complementing gene product and identifying
  • the selected cells are screened for their Mut phenotype by growing them in the presence of methanol and monitoring their growth rate.
  • the expression cassette preferably is integrated into the host genome by transformation of the GS115 host with SacI linearized plasmid pSCD103 comprised of the V, expression cassette.
  • the integration is by addition at a locus or loci having homology with one or more sequences present on the transformation vector. Positive transformants are characterized by
  • Mut + JP_. pastoris strains integrating multiple copies of the expression vector (or of the AMF-V., expression cassette) used for transformation, at the AOXl locus are preferred, since an increase in copy number often increases productivity.
  • P. pastoris transformants which are identified to have the desired genotype and phenotype are grown in fermentors. Typically a three-step production process is used. Initially, cells are grown on a repressing carbon source, preferably excess glycerol. In this stage the cell mass is generated in absence of expression. Next, a period of glycerol limitation growth is allowed, and then a limiting methanol feed is initiated, resulting in the expression of the V, gene driven by the AOXl promoter. It has been found that in the usual pH-range used for heterologous protein production in ⁇ . pastoris (about pH 5.0) the V 1 product suffers a substantial proteolytic degradation.
  • fermentation is preferably performed at pHs below about 3.5, preferably between about pH 2.5 and 3.5, more preferably between about pH 2.5 and 3.0, for example at about pH 2.6.
  • the pH can be adjusted to the desired value by methods known in the art, preferably before the induction of V t production. 5 .
  • the level of CD4-V 1 secreted into the media can, for example, be determined by quantitative Western blot analysis of the media in parallel with a standard (e.g. an EL. coli produced V 1 standard) , using reducing or non- reducing conditions. 0
  • a standard e.g. an EL. coli produced V 1 standard
  • the invention is further illustrated by the following non-limiting examples.
  • the V.,- encoding sequence was excised from this fragment by digestion with EcoRI and Xbal, and isolating the 482 bp fragment (the sequence encoding amino acids 1-106 of 0 mature CD4 along with its leader sequence) on a 1.3% agarose gel ( Figure 2) . Fifty nanograms of the 482 bp fragment were ligated to 100 ng of the plasmid pIBI25, previously cut with EcoRI and Xbal.
  • Plasmid pIBI25 was purchased from IBI, New Haven, CT, and contains an fl 5 origin of replication and the T7 promoter.
  • E. coli MC1061 cells [M.J. Casadaban and S.N. Cohen, J ⁇ Mol. Biol. 38. 179 (1980)] were transformed with ligation products and amp R colonies were selected. Correct plasmid demonstrated a 477bp band upon digestion with EcoRI and Xbal and was called pSCD4.
  • the AMF pre-pro sequence was isolated from M13mpl9 ⁇ MF pre-pro by digesting with EcoRI and BamHI and isolating the about 267 bp fragment on a 1.3% agarose gel.
  • To prepare plasmid M13mpl9 ⁇ MF 15 ⁇ g of plasmid pAO208 (the construction of which is described hereinafter) were digested with Hindlll, filled in with Klenow-fragment DNA polymerase, and digested with EcoRI. The digestion was run on a 1.7% agarose gel and the 267 bp fragment comprised of the AMF pre-pro sequence was isolated.
  • the hEGF (human epidermal growth factor) gene and the AMF pre-pro sequence in the same translational direction were inserted into M13mpl9, (New England Biolabs) , by the following procedure:
  • M13mpl9 ⁇ MF 10 ⁇ g of M13mpl9 were digested with Smal and EcoRI and the large, about 7240 bp plasmid fragment was isolated on a 0.8% agarose gel. The plasmid fragment and the 267 bp AMF fragment were ligated together by T4 DNA ligase. The ligation mixture was transformed into JM103 cells and DNA from the plaque was characterized. The correct plasmid was called M13mpl9 ⁇ MF.
  • pAMFlOl was likewise digested with BajriHI, treated with Klenow fragment of Ej. coli DNA polymerase I, digested with Xbal. and then dephosphorylated. Fifty nanograms of the 477 bp V_,-encoding fragment were ligated to 100 ng of the linearized vector, and the ligation was transformed into E ⁇ . coli CJ236 cells (BioRad, Richmond, CA; Muta-gene 5 . mutagenesis kit, # 170-3571) . Amp R colonies were selected. The correct plasmid exhibited a 740 bp band upon digestion with EcoRI and Xbal and was called pSCDlOl ( Figure 3) .
  • Mutagenesis was performed to fuse the AMF pre- 0 pro sequences directly to the V 1 coding region; the STE2 processing sites (glu-ala-glu-ala) of the AMF pre-pro sequence and the native CD4 leader sequence were eliminated by the oligonucleotide-directed mutagenesis.
  • Single-stranded pSCDlOl template was prepared following 5 the procedure of Russel et al.. Gene 45. 333 (1986) , using the helper phage R408.
  • the mutagenizing and screening oligonucleotide was of the following sequence: 5' GGG TAT CTT TGG ATA AAA GAA AGA AAG TGG TGC TGG GCA A 3 « 0 Mutagenesis reaction products were transformed into MC1061 cells; colonies transformed with the mutagenized plasmid were first identified by hybridization with the screening oligonucleotide, and then the correct mutagenesis was confirmed by sequencing. 5 The correctly mutagenized plasmid was called pSCD102.
  • the plasmid was subsequently digested with Hindlll and the 350 bp fragment isolated from a 10% acrylamide gel and subcloned into pUC18 (Boehringer Mannheim) digested with Hindlll and Sail.
  • the ligation mix was transformed into JM103 cells (that are widely available) and amp R colonies were selected.
  • the correct construction was verified by Hindlll and Sail digestion, which yielded a 350 bp fragment, and was called pA0201. 5 ⁇ g of pA0201 was digested with Hindlll. filled in using . coli DNA Polymerase I Klenow fragment, and 0.1 ⁇ g of Bglll linkers (GAGATCTC) were added. After digestion of the excess Bglll linkers, the plasmid was reclosed and transformed into MC1061 cells. Amp R cells were selected, DNA was prepared, and the correct plasmid was verified by Bglll, Sail double digests, yielding a 350 bp fragment, and by a Hindlll digest to show loss of Hindlll site. This plasmid was called pAO202.
  • the alpha factor-GRF fusion was isolated as a 360 bp BamHI-Pstl partial digest from pYSV201.
  • Plasmid pYSV201 is the EcoRI-BamHI fragment of GRF-E-3 inserted into M13mpl8 (New England Biolabs) . Plasmid GRF-E-3 is described in EP 206,783. 20 ⁇ g of pYSV201 plasmid was digested with BamHI and partially digested with Pstl. To this partial digest was added the following oligonucleotides: 5• AATTCGATGAGATTTCCTTCAATTTTTACTGCA 3' 3' GCTACTCTAAAGGAAGTTAAAAATG 5' .
  • the resulting plasmid, pA0203 was cut with EcoRI and 5 Bglll to yield a fragment of greater than 700 bp.
  • the ⁇ - factor-GRF fragment codes for the (1-40)leu 27 version of GRF and contains the processing sites lys-arg-glu-ala- glu-ala.
  • the AOXl promoter was isolated as a 1900 bp 0 EcoRI fragment from 20 ⁇ g of pAOP3 and subcloned into EcoRI-digested pA0203.
  • the development of pAOP3 is disclosed in EP 226,846 and described hereinbelow.
  • MC1061 cells were transformed with the ligation reaction, amp r colonies were selected, and DNA was prepared.
  • the 5 correct orientation contains a «376 bp Hindlll fragment, whereas the wrong orientation has an «675 bp fragment.
  • One such transformant was isolated and was called pA0204.
  • the parent vector for pA0208 is the HIS4, PARS2 plasmid pYJ32 (NRRL B-15891) which was modified to change 0 the EcoRV site in the tet R gene to a Bglll site, by digesting " PYJ32 with EcoRV and adding Bglll linkers to create pYJ32(+BglII) .
  • This plasmid was digested with Bglll and the 1.75 Kb Bglll fragment from pA0204 containing the AOXl promoter- ⁇ factor GRF-AOXl 3• 5 expression cassette was inserted.
  • the resulting vector was called pA0208.
  • the orientation was verified by an EcoRI digest yielding an 850 bp fragment + vector, as opposed to 1.1 Kb + vector in the other orientation, a. Construction of plasmid pAOP3:
  • Plasmid pPG2.5 [a pBR322 based plasmid
  • This oligonucleotide contains the AOXl promoter sequence up to, but not including, the ATG initiation codon, fused to the sequence of the EcoRI linker;
  • Plasmid pA0815 was constructed by mutagenizing plasmid pA0807 (described hereinbelow) to change the Clal site downstream of the AOXl transcription terminator in pA0807 to a BamHI site.
  • the oligonucleotide used for mutagenizing pA0807 had the following sequence: 5' GAC GTT CGT TTG TGC GGA TCC AAT GCG GTA GTT TAT 3' .
  • the mutagenized plasmid was called pA0807-Bam.
  • Plasmid pA0804 was digested with Bglll and 25 ng of the 2400 bp fragment were ligated to 250 ng of the 5400 bp Bglll fragment from Bglll-digested pA0807-Bam. The ligation mix was transformed into MC1061 cells and the correct construct was verified by digestion with Pst/BamHI to identify 5700 and 2100 bp sized bands. The correct construct was called pA0815. The restriction map of the expression vector pA0815 is shown in Figure 5. a. Plasmid pA0807 was constructed as follows:
  • fl-ori DNA fl bacteriophage DNA 50 ⁇ g was digested with 50 units of Rsa I and Dra I (according to manufacturer's directions) to release the «458 bp DNA fragment containing the fl origin of replication (ori) .
  • the digestion mixture was extracted with an equal volume of phenol: chloroform (V/V) followed by extracting the aqueous layer with an equal volume of chloroform and finally the DNA in the aqueous phase was precipitated by adjusting the NaCl concentration to 0.2M and adding 2.5 volumes of absolute ethanol.
  • the mixture was allowed to stand on ice (4 ⁇ C) for 10 minutes and the DNA precipitate was collected by centrifugation for 30 minutes at 10,000 x g in a microfuge at 4 ⁇ C.
  • the DNA pellet was washed 2 times with 70% aqueous ethanol. The washed pellet was vacuum dried and dissolved in 25 ⁇ l of TE buffer [1.0 mM EDTA in 0.01 M (pH7.4) Tris buffer]. This DNA was electrophoresed on 1.5% agarose gel and the «458 bp fl-ori fragment was electroeluted onto DE81 (Whatman) paper and eluted from the paper in 1M NaCl. The DNA solution was precipitated as detailed above and the DNA precipitate was dissolved in 25 ⁇ l of TE buffer (fl-ori fragment) .
  • the ligation was terminated by heating to 70°C for 10 minutes and then used to transform E_j_ coli strain JM103 [Janisch-Perron et al.. Gene 22, 103 (1983)].
  • Amp R transformants were pooled and superinfected with helper phage R408 [Russel et al.. Supra] . Single stranded phages were isolated from the media and used to reinfect JM103.
  • Amp R transformants contained pBRfl-ori which contains fl-ori cloned into the Dra I sites (nucleotide positions 3232 and 3251) of pBR322.
  • Plasmid pA0804 employed in the above procedure was constructed as follows:
  • Plasmid pBR322 was modified as follows to eliminate the EcoRI site and insert a Bglll site into the PvuII site: 0 pBR322 was digested with EcoRI. the protruding ends were filled in with Klenow Fragment of EL. coli DNA polymerase I, and the resulting DNA was recircularized using T4 ligase. The recircularized DNA was used to transform E. coli MC1061 to a picillin-resistance and 5 transformants were screened for having a plasmid of about 4.37 kbp in size without an EcoRI site. One such transformant was selected and cultured to yield a plasmid, designated pBR322 ⁇ RI, which is pBR322 with the EcoRI site replaced with the sequence: 0 5'-GAATTAATTC-3'
  • PBR322 ⁇ RI was digested with PvuII and the linker, of sequence
  • 3'-GTCTAGAC-5' was ligated to the resulting blunt ends employing T4 ligase.
  • the resulting DNAs were recircularized, also with T4 ligase, and then digested with Bglll and again 0 recircularized using T4 ligase to eliminate multiple
  • Plasmid pBR322 ⁇ RIBGL is the same as pBR322 ⁇ RI except that pBR322 ⁇ RIBGL has the sequence .
  • pBR322 ⁇ RIBGL was digested with a Sail and Bglll and the large fragment (approximately 2.97 kbp) was isolated.
  • Plasmid pBSAGI5I which is described in European Patent Application Publication No. 0,226,752, was digested completely with Bglll and Xhol and an approximately 850 bp fragment from a region of the P. pastoris AOXl locus downstream from the AOXl gene transcription terminator (relative to the direction of transcription from the AOXl promoter) was isolated.
  • the Bglll-Xhol fragment from pBSAGI5I and the approximately 2.97 kbp, Sall-Bglll fragment from pBR322 ⁇ RIBGL were combined and subjected to ligation with T4 ligase.
  • the ligation mixture was used to transform E , coli MC1061 cells to ampicillin-resistance and transformants were screened for a plasmid of the expected size
  • pA0801 (approximately 3.8 kbp) with a Bglll site.
  • This plasmid was designated pA0801.
  • the overhanging end of the Sail site from the PBR322 ⁇ RIBGL fragment was ligated to the overhanging end of the Xhol site on the 850 bp pBSAGI5I fragment and, in the process, both the Sail site and the Xhol site in pA0801 were eliminated.
  • pBSAGI5I was then digested with Clal and the approximately 2.0 kbp fragment was isolated.
  • the 2.0 kbp fragment has an approximately 1.0-kbp segment which comprises the Pj_ pastoris AOXl promoter and transcription initiation site, an approximately 700 bp segment encoding the hepatitis B virus surface antigen ("HBsAg") and an approximately 300 bp segment which comprises the P. pastoris AOXl gene polyadenylation signal and site- encoding segments and transcription terminator.
  • HBsAg hepatitis B virus surface antigen
  • the HBsAg coding segment of the 2.0 kbp fragment is terminated, at the end adjacent the 1.0 kbp segment with the AOXl promoter, with an EcoRI site and, at the end adjacent the 300 bp segment with the AOXl transcription terminator with a StuI site, and has its subsegment which codes for HBsAg oriented and positioned, with respect to 5.
  • the 1.0 kbp promoter-containing and 300 bp transcription terminator-containing segments operatively for expression of the HBsAg upon transcription from the AOXl promoter.
  • the EcoRI site joining the promoter segment to the HBsAg coding segment occurs just upstream (with 0 respect to the direction of transcription from the AOXl promoter) from the translation initiation signal-encoding triplet of the AOXl promoter.
  • Plasmid pA0801 was cut with Clal and combined for ligation using T4 ligase with the approximately 2.0 0 kbp Clal-site-terminated fragment from pBSAGI ⁇ l.
  • the ligation mixture was used to transform E coli MC1061 to ampicillin resistance, and transformants were screened for a plasmid of the expected size (approximately 5.8 kbp) which, on digestion with Clal and Bglll. yielded 5 fragments of about 2.32 kbp (with the origin of replication and ampicillin-resistance gene from pBR322) and about 1.9 kbp, 1.48 kbp, and 100 bp.
  • the plasmid yielded an approximately 2.48 kbp fragment with the 300 bp 0 terminator segment from the AOXl gene and the HBsAg coding segment, a fragment of about 900 bp containing the segment from upstream of the AOXl protein encoding segment of the AOXl gene in the AOXl locus, and a fragment of about 2.42 kbp containing the origin of 5 replication and ampicillin resistance gene from pBR322 and an approximately 100 bp Clal-Bglll segment of the AOXl locus (further upstream from the AOXl-encoding segment than the first mentioned 900 bp EcoRI-Bglll segment) .
  • Such a plasmid had the Clal fragment from pBSAGI5I in the desired orientation, in the opposite undesired orientation, there would be EcoRI-Bglll fragments of about 3.3 kbp, 2.38 kbp and 900 bp.
  • pA0802 One of the transformants harboring the desired plasmid, designated pA0802, was selected for further work and was cultured to yield that plasmid.
  • the desired orientation of the Clal fragment from pBSAGISI in pA0802 had the AOXl gene in the AOXl locus oriented correctly to lead to the correct integration into the
  • pA0802 was then treated to remove the HBsAg coding segment terminated with an EcoRI site and a StuI site.
  • the plasmid was digested with StuI and a linker of sequence:
  • 5'-GGAATTCC-3' 3'-CCTTAAGG-5' was ligated to the blunt ends using T4 ligase.
  • the mixture was then treated with EcoRI and again subjected to ligating using T4 ligase.
  • the ligation mixture was then used to transform EL coli MC1061 cells to ampicillin resistance and transformants were screened for a plasmid of the expected size (5.1 kbp) with EcoRI-Bglll fragments of about 1.78 kbp, 900 bp, and 2.42 kbp and Bglll-Clal fragment of about 100 bp, 2.32 kbp, 1.48 kbp, and 1.2 kbp.
  • This plasmid was designated pA0803.
  • a transformant with the desired plasmid was selected for further work and was cultured to yield pA0803.
  • Plasmid pA0804 was then made from pA0803 by inserting, into the BamHI site from pBR322 in pA0803, an approximately 2.75 kbp Bglll fragment from the P. pastoris HIS4 gene. See, e.g., Cregg et al.. Mol. Cell. Biol. 5 . , 3376 (1985) and European Patent Application Publication Nos. 0,180,899 and 0,188,677.
  • pA0803 was digested with BamHI and combined with the HIS4 gene-containing Bglll site-terminated fragment and the 5 . mixture subjected to ligation using T4 ligase.
  • pA0804 has one Sall-Clal fragment of about 1.5 kbp and another of about 5.0 kbp and a Clal-Clal fragment of 1.3 kbp; this indicates that the direction of 5 transcription of the HIS4 gene in the plasmid is the same as the direction of transcription of the ampicillin resistance gene and opposite the direction of transcription from the AOXl promoter.
  • the orientation of the HIS4 gene is pA0804 is 0 not critical to the function of the plasmid or of its derivatives with cDNA coding segments inserted at the EcoRI site between the AOXl promoter and terminator segments.
  • a plasmid with the HIS4 gene in the orientation opposite that of the HIS4 gene in pA0804 5 would also be effective for use in accordance with the present invention.
  • Plasmid pSCD103 was used to develop Mut + and Mut * strains of
  • the His " strain GS115 was the host for all transformations. Transformations were accomplished by the whole-cell LiCl method [Ito et al.. J. Bacteriol. 153(1). 163 (1983)], 5 with minor modification necessary for adaptation to P. pastoris.
  • pSCD103 was digested with Sad, which linearizes the vector within the AOXl promoter region, and 10 ⁇ g of the linearized vector were used to transform GS115. Histidine prototrophs were selected.
  • pSCD103 was digested with Bglll thereby liberating an expression cassette comprised of the AOXl promoter region, ⁇ MF leader-V 1 gene, AOXl transcription termination signals, HIS4 gene for selection, and AOXl 3' region. Both ends of this expression cassette contain long sequences which are homologous to the 5' and 3' ends of the AOXl locus. 10 ⁇ g of the linearized vector were used to transform GS115 cells. Histidine prototrophs were selected and screened for the Mut " phenotype by replica plating colonies from glucose containing media to methanol containing media, and evaluating growth rate on methanol. Slow growth on methanol was indicative of the Mut " phenotype. Several His + Mut " colonies were identified.
  • Fermentation in two-liter fermentors a Fermentor start-up and general operation
  • the 2-liter fermentors (Biolafitte, LSL Biolafitte, Princeton, NJ) were autoclaved at a volume of one liter containing 5X Basal Salts (21 ml/1 85% phosphoric acid, 0.9 g/1 Calcium Sulfate x 2H 2 0, 14.3 g/1 Potassium Sulfate, 11.7 g/1 Magnesium Sulfate x 7H20, 3.25 g/1 Potassium Hydroxide) and 5% (w/v) glycerol. After sterilization, 5 ml of a PTM, trace salts solution 5 . (6.0 g/1 Cupric Sulfate x 5H 2 0, 0.08 g/1 Sodium Iodide,
  • the fermentors were then inoculated with 50 ml 5 of an overnight culture grown in 6.75 g/1 Difco yeast nitrogen base, 2% glycerol, 0.1 M potassium phosphate, pH 6.0. After 16 hours of fermentor growth, the pH of the medium was dropped to 2.6 and the cells continued to grow in a batch mode to exhaust the original charge of 0 glycerol. Upon glycerol exhaustion, a 50% (w/v) glycerol feed containing 12 ml/1 PTM 1 trace salts was initiated at a feed rate of 5 to 20 ml/h.
  • a 100 % methanol feed containing 12 ml/1 PTM, trace salts was 5 initiated at 1 ml/h, and the glycerol feed was shut off after 1 hour of methanol feeding.
  • the methanol feed was increased to 5-6 ml/h over an 8-12 hour period and was maintained at this rate for the remainder of the fermentation.
  • the 0 dissolved oxygen concentration was maintained above 20% of saturation by adjusting agitation and aeration as needed.
  • the temperature was controlled at 30 ⁇ C and foaming was controlled by the addition of a 5% solution of Struktol J-673 antifoam 5 (Struktol Co. , Stow, OH) .
  • Run 568 G+SCD103S03 Run 570: G+SCD103S16 Run 571: G-SCD103S03 Run 585: G+SCD103S03 10. Run 593: G+SCD103S16
  • Figure 6 shows the time course for cell yield for one-liter fermentation runs with strains G+SCD103S03 (Run 568), G+SCD103S16 (Run 570), and G-SCD103S03 (Run 0 571) .
  • Cell yield was calculated as the mass of wet cells per liter of broth after centrifugation. A conversion factor of 0.25 was used to calculate yield of dry cells per liter.
  • Figures 7A and 7B show the time course for cell yield and CD4-V, production, respectively,., for 5 fermentation Run 593.
  • the expression level was determined for unfiltered, reduced broth samples, and was estimated by quantitative Western blot analysis to be 130 mg/liter after 71 hours on methanol. The level was continuing to increase when the fermentor was harvested.
  • Example 4 Analysis of secreted CD4-V, a. Western blot analysis
  • the V, region of CD4 contains a single disulfide bond between two cysteine residues, which are located at positions 16 and 84 of the mature CD4, near the N- and C-
  • the 2x sample buffer lacked any reducing agent (-DTT) .
  • Fermentor samples and 2X sample buffer were mixed and immediately boiled for 5 minutes (+DTT) , or mixed and immediately placed at room temperature until the gel was loaded (-DTT) . Samples thus prepared were
  • Pichia- 35 produced recombinant CD4-V, by determining the N-terminal sequence of the protein which co igrates with the v 1 standard on reducing SDS-PAGE.
  • control fermentor broth obtained from the fermentation of Pichia strain G-PA0815 does not contain a protein which comigrates with the V, 5 . standard.
  • Pichia rCD4-V 1 appears to be the major lower molecular weight protein species present in broth samples from the fermentation of strain G+SCD103S16.
  • the pH of the broth samples was raised to 5.0 and the samples incubated under the same conditions as before ( Figure 10, lanes 5-7) . As seen in the Figure, some broadening of the intact V, band occurred under these conditions. Therefore, while the rCD4-V 1 is stable in the pH 2.5 broth samples, some degree of proteolytic degradation may occur in samples at elevated pHs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La production de recombinaison d'une forme soluble sécrétée de la protéine CD4 (une glycoprotéine qui est exprimée sur la membrane cellulaire, lymphocytes (T) dérivés de la glande thymus) utilise un système d'expression P. pastoris. L'invention concerne également des fragments ADN qui sont utiles pour l'expression CD4 dans P. pastoris, des vecteurs d'expression contenant de tels fragments d'ADN, des cellules de levure transformées à l'aide de ces fragments ADN ou des vecteurs, et la glycoprotéine CD4 humaine sensiblement pure ainsi produite.
PCT/US1990/005520 1989-09-28 1990-09-27 Production de cd4 dans pichia pastoris Ceased WO1991005057A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41393889A 1989-09-28 1989-09-28
US413,938 1989-09-28

Publications (1)

Publication Number Publication Date
WO1991005057A1 true WO1991005057A1 (fr) 1991-04-18

Family

ID=23639282

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/005520 Ceased WO1991005057A1 (fr) 1989-09-28 1990-09-27 Production de cd4 dans pichia pastoris

Country Status (1)

Country Link
WO (1) WO1991005057A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541112A (en) * 1991-04-01 1996-07-30 Salk Institute Biotechnology/Industrial Associates Genes which influence pichia proteolytic activity, and uses therefor
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
WO2002000856A3 (fr) * 2000-06-30 2003-01-03 Flanders Interuniversity Inst Modification de glycosylation de proteine dans pichia pastoris
US7507573B2 (en) 2003-11-14 2009-03-24 Vib, Vzw Modification of protein glycosylation in methylotrophic yeast

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929578A (en) * 1973-11-09 1975-12-30 Mitsubishi Gas Chemical Co Process for cultivating ethanol-assimilating yeasts
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4808534A (en) * 1977-01-10 1989-02-28 Schick Josef H Method and apparatus for the microbiological production of single-cell protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929578A (en) * 1973-11-09 1975-12-30 Mitsubishi Gas Chemical Co Process for cultivating ethanol-assimilating yeasts
US4808534A (en) * 1977-01-10 1989-02-28 Schick Josef H Method and apparatus for the microbiological production of single-cell protein
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIO/TECHNOLOGY, Volume 5, issued May 1987, J.M. CREGG et al., "High-level expression and efficient assembly of hepatitis B surface antigen in the methylo-trophic yeast, Pichia pastoris", pages 479-185. *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Volume 85, issued April 1988, E.A. BERGER et al., "A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus", pages 2357-2361. *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5691166A (en) * 1991-04-01 1997-11-25 Sibia Neurosciences, Inc. Genes which influence pichia proteolytic activity, and uses therefor
US5831053A (en) * 1991-04-01 1998-11-03 Sibia Neurosciences, Inc. Genes which influence pichia proteolytic activity, and uses therefor
US6051419A (en) * 1991-04-01 2000-04-18 Sibia Neurosciences, Inc. Genes which influence pichia proteolytic activity, and uses therefor
US5541112A (en) * 1991-04-01 1996-07-30 Salk Institute Biotechnology/Industrial Associates Genes which influence pichia proteolytic activity, and uses therefor
US8663971B2 (en) 2000-06-30 2014-03-04 Vib, Vzw Protein glycosylation modification in methylotrophic yeast
WO2002000856A3 (fr) * 2000-06-30 2003-01-03 Flanders Interuniversity Inst Modification de glycosylation de proteine dans pichia pastoris
EP2028275A3 (fr) * 2000-06-30 2009-05-06 VIB vzw Modification de glycosylation de protéine dans pichia pastoris
EP2267135A3 (fr) * 2000-06-30 2011-09-14 Vib Vzw Modification de glycosylation de protéine dans pichia pastoris
US9359628B2 (en) 2000-06-30 2016-06-07 Vib, Vzw Protein glycosylation modification in methylotrophic yeast
US8354268B2 (en) 2000-06-30 2013-01-15 Vib, Vzw Protein glycosylation modification in methylotrophic yeast
US7507573B2 (en) 2003-11-14 2009-03-24 Vib, Vzw Modification of protein glycosylation in methylotrophic yeast
US8058053B2 (en) 2003-11-14 2011-11-15 Vib, Vzw Modification of protein glycosylation in methylotrophic yeast

Similar Documents

Publication Publication Date Title
US5324639A (en) Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5102789A (en) Production of epideramal growth factor in pichia pastoris yeast cells
EP0329203B1 (fr) Système d'expression pour levure avec des vecteurs contenant le promoteur PyK et synthèse de protéines étrangères
EP0123811B1 (fr) Utilisation du promoteur GAL 1 de levure
JP3276933B2 (ja) エリスロポエチン活性を有する糖蛋白質の製造方法
FI94427B (fi) Säätelyalue heterologista geeni-ilmaisua varten hiivassa
JP2793215B2 (ja) 先端を切断したα―因子リーダー配列を用いた酵母における異種タンパクの改良された発現および分泌
JP3315689B2 (ja) 治療的機能を有するアルブミンの誘導体
EP0243465A1 (fr) Procede d'utilisation de bar1 pour la secretion de proteines etrangeres
US5612198A (en) Production of insulin-like growth factor-1 in methylotrophic yeast cells
WO1992013951A1 (fr) Production de serumalbumine humaine dans des cellules de levure methylotrophique
US5258302A (en) DNA for expression of aprotinin in methylotrophic yeast cells
EP0631627A1 (fr) Procede de production de proteines dans la levure
WO1991005057A1 (fr) Production de cd4 dans pichia pastoris
JPS6363199B2 (fr)
EP1211314A2 (fr) Expression d'un précurseur de l'insuline humaine dans p. pastoris
WO1990002810A1 (fr) Production de polypeptides d'interleukine-2 dans des cellules de levure de pichia pastoris
JPH05213998A (ja) 新規なポリペプチド及びこれを有効成分とする 医薬組成物
EP0259615A1 (fr) Récepteur Fc epsilon humain avec affinité réduite, sa préparation et sa purification
EP0547171A1 (fr) Production de lisozyme humain dans des cellules de levure methylotrophe et ses secretions efficaces
EP0258492A1 (fr) Récepteur Fc-epsilon humain à affinité réduite, son isolement et sa purification
EP0388008A1 (fr) Préparation de superoxyde dismutase dans des cellules de levure pichia pastoris
AU1593688A (en) Immunogenic polypeptide and method for purifying it
Yost et al. Purification of biologically active SPARC expressed in Saccharomyces cerevisiae
US6613547B1 (en) Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 1 promoter and terminator

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA